D. E. Shaw & Co., Inc. Rigel Pharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.67 - $11.9 $866,688 - $15.4 Million	-1,293,565 Reduced 27.84%	3,352,899 $5.03 Million
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $1.29 Million - $14.3 Million	1,171,928 Added 33.73%	4,646,464 $5.48 Million
Q2 2022 Aug 15, 2022	BUY	$0.67 - $3.19 $1.97 Million - $9.38 Million	2,940,803 Added 550.99%	3,474,536 $3.93 Million
Q1 2022 May 16, 2022	BUY	$2.22 - $3.45 $1 Million - $1.56 Million	451,446 Added 548.62%	533,733 $1.6 Million
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $110,119 - $166,579	-46,661 Reduced 36.19%	82,287 $218,000
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $451,318 - $580,266	128,948 New	128,948 $468,000
Q1 2021 May 17, 2021	SELL	$3.35 - $4.93 $156,344 - $230,083	-46,670 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.35 - $3.74 $218,528 - $347,786	-92,991 Reduced 66.58%	46,670 $163,000
Q3 2020 Nov 16, 2020	SELL	$1.78 - $4.13 $1.55 Million - $3.59 Million	-869,752 Reduced 86.16%	139,661 $335,000
Q2 2020 Aug 14, 2020	BUY	$1.41 - $2.05 $853,409 - $1.24 Million	605,255 Added 149.76%	1,009,413 $1.85 Million
Q1 2020 May 15, 2020	SELL	$1.27 - $3.0 $50,563 - $119,442	-39,814 Reduced 8.97%	404,158 $630,000
Q4 2019 Feb 14, 2020	SELL	$1.6 - $2.43 $159,435 - $242,142	-99,647 Reduced 18.33%	443,972 $950,000
Q3 2019 Nov 14, 2019	BUY	$1.63 - $2.62 $477,694 - $767,827	293,064 Added 116.97%	543,619 $1.02 Million
Q2 2019 Aug 14, 2019	BUY	$2.02 - $2.61 $322,236 - $416,355	159,523 Added 175.24%	250,555 $654,000
Q1 2019 May 15, 2019	SELL	$2.0 - $2.65 $44,550 - $59,028	-22,275 Reduced 19.66%	91,032 $234,000
Q4 2018 Feb 14, 2019	SELL	$2.08 - $3.36 $250,596 - $404,809	-120,479 Reduced 51.53%	113,307 $261,000
Q3 2018 Nov 14, 2018	SELL	$2.6 - $3.59 $1.07 Million - $1.47 Million	-410,173 Reduced 63.7%	233,786 $750,000
Q2 2018 Aug 14, 2018	SELL	$2.83 - $4.11 $503,974 - $731,921	-178,083 Reduced 21.66%	643,959 $1.82 Million
Q1 2018 May 15, 2018	SELL	$3.54 - $4.54 $2.61 Million - $3.34 Million	-736,383 Reduced 47.25%	822,042 $2.91 Million
Q4 2017 Feb 14, 2018	BUY	$3.23 - $4.3 $152,546 - $203,080	47,228 Added 3.13%	1,558,425 $6.05 Million
Q3 2017 Nov 14, 2017	BUY	$2.18 - $2.57 $3.29 Million - $3.88 Million	1,511,197	1,511,197 $3.84 Million

Others Institutions Holding RIGL

# of Institutions

Shares Held

335K

Call Options Held

Put Options Held

Telemetry Investments, L.L.C. New York, NY

323K
Shares

$7.34 Million
0.76% of portfolio
Bergan Kdv Wealth Management, LLC

10K
Shares

$227,600
0.0% of portfolio
Ifp Advisors, Inc

1K
Shares

$22,760
0.0% of portfolio
Farther Finance Advisors, LLC San Francisco, CA

667
Shares

$15,180
0.0% of portfolio
Nelson, Van Denburg & Campbell Wealth Management Group, LLC Omaha, NE

356
Shares

$8,102
0.0% of portfolio

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $3.93B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account